Low Cardiac Output, Ventricular Fibrillation, Ventricular Tachycardia
Conditions
Brief summary
This study assesses the 18-month incidence of inappropriate shocks in subjects implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) for primary prevention of sudden cardiac death. Devices are to be programmed with zone cutoffs at 200 bpm and 250 bmp in order to mimic the programming settings for transvenous ICDs in the MADIT RIT study. The incidence of inappropriate S-ICD shocks will be compared to the incidence of inappropriate shocks observed in the MADIT RIT study.
Detailed description
Implantable cardioverter defibrillator (ICD) therapy is highly effective for reducing mortality in patients with clinical markers for elevated risk for ventricular arrhythmias. However, inappropriate shocks and unnecessary appropriate shocks remain an important side effect that can significantly affect an ICD recipient's quality of life and may be deleterious to the myocardium. The MADIT RIT study demonstrated that the incidence of inappropriate and unnecessary appropriate ICD therapy can be reduced in primary prevention patients through two different programming strategies: 1) High Rate Zone Cutoff, i.e., raising the lowest rate detection cutoff to 200 bpm; and 2) Delayed Therapy Initiation, i.e., increasing the time to therapy initiation to 60 seconds for arrhythmias detected between 170-199 bpm and 12.5 seconds between 200-249 bpm. Both strategies effectively reduced the amount of ICD therapy delivered when compared to conventional programming, where the lowest rate detection cutoff was 170 bpm and the delay to therapy initiation was programmed to 2.5 seconds. Importantly, neither treatment arm was associated with significantly increased syncope or mortality. The results of MADIT RIT established preferred device settings for reducing shocks in transvenous ICD (TV-ICD) patients with a primary prevention indication. Preferred settings for subcutaneous ICDs, however, have not been established with data from prospective studies. The UNTOUCHED study will test a programming scheme designed to minimize inappropriate and unnecessary shocks in patients who have an indication for primary prevention of sudden cardiac death and low ejection fraction. Although S-ICD programming options do not permit exact replication of the programmed settings previously shown to reduce shocks in the MADIT RIT treatment arms, key elements are combined into the UNTOUCHED settings to be tested in this protocol. It is hypothesized that despite the lack of anti-tachycardia pacing, the EMBLEM S-ICD settings utilized in this study will result in an overall shock incidence similar to that observed in ICD patients from MADIT RIT.
Interventions
The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
Sponsors
Study design
Eligibility
Inclusion criteria
* Patient with ischemic or non-ischemic heart disease who meets current guidelines for ICD therapy and intends to undergo a de novo implant procedure for an EMBLEM™ S-ICD (or newer generation BSC S-ICD) * Left ventricular ejection fraction ≤ 35% * A passing EMBLEM™ S-ICD (or newer generation BSC S-ICD) screening ECG * Patient ≥ 21 years of age willing and capable of giving informed consent * Patient willing and capable of complying with follow-up visits
Exclusion criteria
* Patient with a history of spontaneous sustained VT or VF * Patient with bradycardia pacing indication * Patient eligible and scheduled for cardiac resynchronization implant * Patient with a previous S-ICD or a previous transvenous pulse generator (pacemaker or defibrillator) * Patient in NYHA Class IV documented in the medical records within 90 days before enrollment * Patient with life expectancy shorter than 18 months due to any medical condition (e.g., cancer, uremia, liver failure, etc…) * Patient receiving hemodialysis within 180 days before to enrollment * Patients unable to give consent in person, including patients unable to read or write * Patient who is known to be pregnant or plans to become pregnant over the course of the trial * Patient unwilling or unable to cooperate with the protocol * Participation in concurrent clinical study without prior approval from Boston Scientific * Medical status (e.g., hemodynamic conditions ) of the patient doesn't allow programming devices with a conditional shock zone at 200 bpm and a shock zone at 250 bpm, in the judgment of the implanting physician and/or according to (inter) national guidelines
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients Who Did Not Experience an Inappropriate Shock From Their EMBLEM S-ICD | 18 months | Primary endpoint: Inappropriate shock free rate from 0 to 540 Days (18-Months) compared to a performance goal of 91.6%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Not Experiencing a System or Procedure Related Complication From 0 to 30 Days | 30 days | Secondary safety endpoint: Freedom from System and Procedure Related Complications at 30 days compared to a performance goal of 93.8%. |
| Percentage of Subjects Free From All-cause Shock From Their EMBLEM S-ICD | 18 months | Secondary efficacy endpoint: All-Cause Shock Free Rate at 540 days (18-months) compared to a performance goal of 85.8%. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients Not Experiencing a System or Procedure Related Complication From 0 to 180 Days (6 Months). | 6 months | Post-Market Clinical Follow-up (PMCF) Endpoint: Freedom from System and Procedure Related Complications at 180 days (6 months) compared to a performance goal of 85%. This analysis was conducted for two sub-groups of UNTOUCHED Study subjects: 1.) the first 200 subjects implanted with an EMBLEM model A209 device; 2.) the first 200 subjects implanted with an EMBLEM model A219 device. The PMCF analysis prespecified in the study protocol only required a sub-set of the implanted UNTOUCHED Study subjects (i.e., 200 subjects for the EMBLEM A209 analysis and 200 for the EMBLEM A219 analysis; the full study cohort was not required for these two analyses). |
Countries
Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Puerto Rico, Spain, Switzerland, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| UNTOUCHED Implanted/Attempted Subjects UNTOUCHED Study subjects who were implanted or attempted for implant with an EMBLEM S-ICD with rate zones set at 200 bpm and 250 bpm per protocol.
EMBLEM S-ICD System: The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp. | 1,116 |
| Total | 1,116 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 57 |
| Overall Study | Screen Failures | 55 |
| Overall Study | Total Withdrawals | 209 |
Baseline characteristics
| Characteristic | UNTOUCHED Implanted/Attempted Subjects |
|---|---|
| Age, Continuous | 55.8 years STANDARD_DEVIATION 12.4 |
| Race/Ethnicity, Customized Asian | 20 Participants |
| Race/Ethnicity, Customized Black | 239 Participants |
| Race/Ethnicity, Customized Caucasian | 704 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 53 Participants |
| Race/Ethnicity, Customized Native American | 6 Participants |
| Race/Ethnicity, Customized Other | 8 Participants |
| Race/Ethnicity, Customized Pacific Islander | 3 Participants |
| Race/Ethnicity, Customized Unknown | 83 Participants |
| Region of Enrollment Canada | 16 participants |
| Region of Enrollment Europe | 292 participants |
| Region of Enrollment Puerto Rico | 1 participants |
| Region of Enrollment United States | 807 participants |
| Sex: Female, Male Female | 286 Participants |
| Sex: Female, Male Male | 830 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 57 / 1,116 |
| other Total, other adverse events | 155 / 1,116 |
| serious Total, serious adverse events | 354 / 1,116 |
Outcome results
Percentage of Patients Who Did Not Experience an Inappropriate Shock From Their EMBLEM S-ICD
Primary endpoint: Inappropriate shock free rate from 0 to 540 Days (18-Months) compared to a performance goal of 91.6%.
Time frame: 18 months
Population: All implanted subjects were included in the analysis except for one participant who was co-enrolled in another study that may have affected the results of this analysis. There were 4 subjects who were attempted to be implanted but did not receive a device and therefore not included in the analysis. The endpoint was analyzes using intent to treat analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| S-ICD | Percentage of Patients Who Did Not Experience an Inappropriate Shock From Their EMBLEM S-ICD | 95.9 Percentage of participants |
Percentage of Participants Not Experiencing a System or Procedure Related Complication From 0 to 30 Days
Secondary safety endpoint: Freedom from System and Procedure Related Complications at 30 days compared to a performance goal of 93.8%.
Time frame: 30 days
Population: All implanted and attempted subjects were included in the analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| S-ICD | Percentage of Participants Not Experiencing a System or Procedure Related Complication From 0 to 30 Days | 95.8 Percentage of participants |
Percentage of Subjects Free From All-cause Shock From Their EMBLEM S-ICD
Secondary efficacy endpoint: All-Cause Shock Free Rate at 540 days (18-months) compared to a performance goal of 85.8%.
Time frame: 18 months
Population: All implanted subjects were included in the analysis except for one participant who was co-enrolled in another study that may have affected the results of this analysis. There were 4 subjects who were attempted to be implanted but did not receive a device and therefore not included in the analysis. The endpoint was analyzes using intent to treat analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| S-ICD | Percentage of Subjects Free From All-cause Shock From Their EMBLEM S-ICD | 90.6 Percentage of participants |
Percentage of Patients Not Experiencing a System or Procedure Related Complication From 0 to 180 Days (6 Months).
Post-Market Clinical Follow-up (PMCF) Endpoint: Freedom from System and Procedure Related Complications at 180 days (6 months) compared to a performance goal of 85%. This analysis was conducted for two sub-groups of UNTOUCHED Study subjects: 1.) the first 200 subjects implanted with an EMBLEM model A209 device; 2.) the first 200 subjects implanted with an EMBLEM model A219 device. The PMCF analysis prespecified in the study protocol only required a sub-set of the implanted UNTOUCHED Study subjects (i.e., 200 subjects for the EMBLEM A209 analysis and 200 for the EMBLEM A219 analysis; the full study cohort was not required for these two analyses).
Time frame: 6 months
Population: The first 200 UNTOUCHED Study subjects implanted with an EMBLEM model A209 device as well as the first 200 UNTOUCHED Study subjects implanted with an EMBLEM model A219 device
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| S-ICD | Percentage of Patients Not Experiencing a System or Procedure Related Complication From 0 to 180 Days (6 Months). | 93.5 Percentage of participants |
| S-ICD (EMBLEM Model A219) | Percentage of Patients Not Experiencing a System or Procedure Related Complication From 0 to 180 Days (6 Months). | 93.5 Percentage of participants |